ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities; Program Announcements Released By NCI

May 21, 1999

Alliteration And Prayer Were Andrew von Eschenbach’s Tools For Making Progress Possible For People.

May 19, 2006

RFA On Breast Cancer Low Fat Diet Available

November 25, 1983

Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint

March 25, 2011

Herberman Outlines NSABP restructuring In Plan To NCI

May 6, 1994

Also in this 8-page issue: Use cancer mortality, not 5-year survival, to track progress against cancer, researchers say.

July 29, 2005